HS
RLAY icon

HighVista Strategies’s Relay Therapeutics RLAY Stock Holding History

HighVista Strategies’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.47M Buy
506,235
+84,354
+20% +$1.22M 2.16% 7
2026
Q1 		$4.2M Sell
421,881
-123,198
-23% -$1.1M 1.16% 17
2025
Q4 		$4.61M Buy
545,079
+304,620
+127% +$2.17M 1.19% 24
2025
Q3 		$1.26M Buy
240,459
+90,758
+61% +$346K 0.31% 104
2025
Q2 		$518K Buy
+149,701
New +$445K 0.19% 125
2023
Q3 		– Sell
-32,197
Closed -$404K – 159
2023
Q2 		$404K Sell
32,197
-97,048
-75% -$1.21M 0.19% 123
2023
Q1 		$2.13M Sell
129,245
-47,276
-27% -$848K 1.73% 21
2022
Q4 		$2.64M Buy
176,521
+9,138
+5% +$175K 1.57% 18
2022
Q3 		$3.74M Buy
167,383
+54,070
+48% +$1.19M 2.14% 9
2022
Q2 		$1.9M Buy
113,313
+44,705
+65% +$958K 1.15% 28
2022
Q1 		$2.05M Buy
68,608
+22,616
+49% +$549K 1.31% 21
2021
Q4 		$1.41M Buy
45,992
+8,249
+22% +$261K 1.12% 25
2021
Q3 		$1.19M Buy
37,743
+14,493
+62% +$488K 0.79% 38
2021
Q2 		$851K Buy
23,250
+6,374
+38% +$210K 0.6% 34
2021
Q1 		$583K Buy
16,876
+1,901
+13% +$82.5K 0.43% 61
2020
Q4 		$622K Buy
+14,975
New +$677K 0.4% 63

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

HighVista Strategies's RLAY Position: Q2 2026 in Review

HighVista Strategies increased its Relay Therapeutics (RLAY) stake by 20% in Q2 2026, buying an estimated $1.22M and bringing the position to 506,235 shares worth $9.47M. The position accounts for 2.16% of the portfolio, ranked #7.

HighVista Strategies first reported a position in RLAY in Q4 2020 and has held it in 16 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • HighVista Strategies held 506,235 shares of Relay Therapeutics worth $9.47M as of Q2 2026.
  • HighVista Strategies bought 84,354 Relay Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Relay Therapeutics made up 2.16% of HighVista Strategies's portfolio in Q2 2026, its #7 holding.
  • HighVista Strategies first reported a position in Relay Therapeutics in Q4 2020 and has held it in 16 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.